[出版论文]

“Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201”
(Cho et al. 2024. Lung Cancer. 190:107509)

[出版论文]

“Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset”
(Lee et al. 2024. Cancer Res Treat. 56(1):48-60)

[出版论文]

“Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced: NSCLC: A LASER301 Subset Analysis”
(Soo et al. 2023. J Thorac Oncol. 18(12):1756-1766)

[出版论文]

“Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301”
(Reungwetwattana et al. 2023. J Thorac Oncol. 18(10):1351-1361)

[出版论文]

“Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301”
(Cho et al. 2023. J Clin Oncol. 41(26):4208-4217)

[出版论文]

“Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer”
(Huh et al. 2023. Lung Cancer. 175:112-120)

[出版论文]

“Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer”
(Huh et al., 2023. Lung Cancer. 175:112-120)

[出版论文]

“Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer”
(Kim et al., 2022. Adv Ther. 39(10):4757-4771)

[出版论文]

“A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors”
Cho et al., 2021. J Thorac Oncol. 17(4):558-567

[出版论文]

"Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies"
(Jang et al., 2021. JTO Clin Res Rep. 2(10): 100224)

[出版论文]

"Lazertinib: First Approval"
(Dhillon S. 2021. Drugs. 81:1107-1113)

[出版论文]

"EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation"
(Park et al., 2020. Cancer Res Treat. 52(4):1288-1290)

[出版论文]

"YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small cell lung cancer"
(Yun et al., 2019. Clin Cancer Res. 25(8):2575-2587)

[出版论文]

"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study"
(Ahn et al., 2019. Lancet Oncol. 20(12):1681-1690)

[学会发表]

“Lazertinib as a frontline treatment in patients with EGFR mutant advanced non-small cell lung cancer: overall survival from LASER201”
发表海报 (2023 AACR-KCA)

[学会发表]

“Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-naïve Patients With Epidermal Growth Factor Receptor–mutated Advanced Non-Small Cell Lung Cancer: Analysis of the Asian Subpopulation in LASER301”
演讲 (2023 Asian Oncology Society)

[学会发表]

“Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-mutated Advanced Non-Small Cell Lung Cancer: A LASER301 Subset Analysis”
演讲 & 发表海报 (2023 ESMO)

[学会发表]

“Cerebrospinal fluid pharmacokinetic study of Lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG 21-01 LAZARUS trial”
发表海报 (2023 ESMO)

[学会发表]

“MANAGEMENT OF PARESTHESIA IN PATIENTS TREATED WITH LAZERTINIB: INTEGRATED ANALYSIS OF LASER201 AND LASER301 STUDIES”
发表海报 (2023 ESMO)

[学会发表]

“Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single arm, phase II multi center trial”
演讲 (2023 WLCL)

[学会发表]

“Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-naïve Patients With Epidermal Growth Factor Receptor–mutated Advanced Non-Small Cell Lung Cancer: Analysis of the Asian Subpopulation in LASER301”
发表海报 (2023 WCLC)

[学会发表]

“LAZERTINIB VS GEFITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH EGFRm ADVANCED NSCLC : LASER301”
演讲 (2022 ESMO)

[学会发表]

“Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial”
发表海报 (2022 WLCL)

[学会发表]

“Overall survival in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib: Results from the Phase I/II study (LASER201)”
演讲 (2022 Asian Oncology Society)

[学会发表]

“Characterization of the Absorption, Metabolism and Excretion Pathways of Lazertinib in Humans”
发表海报 (2022 AACP)

[学会发表]

“Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive, metastatic NSCLC patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (KCSG LU20-15)”
发表海报 (2022 ASCO)

[学会发表]

“Effects of Food and Race on Pharmacokinetics of Lazertinib in Healthy Volunteers and Patients with EGFR Mutation Positive Advanced Non-small Cell Lung Cancer”
发表海报 (2021 AAPS)

[学会发表]

“Efficacy and Safety of Lazertinib 240 mg in Patients with EGFR T790M Mutant NSCLC: Data from a Phase I/II Study”
发表海报 (2021 Korean Association for Lung Cancer International Conference)

[学会发表]

"Cardiac Safety Assessment of Lazertinib in Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer"
演讲 (2020 WCLC)

[学会发表]

"ctDNA Resistance Landscape of Lazertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor (TKI)"
发表海报 (2020 ASCO)

[学会发表]

"Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC : Data from a phase I/II study"
发表海报 (2020 ASCO)

[学会发表]

"Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study"
发表海报 (2020 ASCO)

[学会发表]

"Lazertinib, a 3rd Generation EGFR‐TKI, in Patients with EGFR‐TKI resistant NSCLC: Updated Results of Phase I/II Study"
发表海报 (2019 ASCO)

[学会发表]

"Lazertinib, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI resistant NSCLC: Updated Results of Phase I/II Study"
演讲 (2019 KSMO)
KSMO 홈페이지 이전으로 현재 구축 중

[学会发表]

"Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Updated Results of a Phase I/II Study"
演讲 (2018 WCLC)

[学会发表]

"YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC"
发表海报 (2018 AACR)

[学会发表]

"YH25448, a 3rd Generation EGFR‐TKI, in Patients with EGFR‐TKI‐resistant NSCLC: Phase I/II Study Results"
发表海报 (2018 ASCO)

[学会发表]

"YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC"
发表海报 (2016 WCLC)